Abstract
The effect of the chemopreventive synthetic retinoid N -(4-hydroxyphenyl)-retinamide (4-HPR) on aromatase activity and expression was examined. 4-HPR caused a dose-dependent inhibition of aromatase activity in microsomes isolated from JEG-3 human placental carcinoma cells. The kinetics of inhibition were analysed by double-reciprocal plot. The Km of the substrate increased and the Vmax of the reaction decreased in the presence of 4-HPR, indicating that enzyme inhibition involved both competition for the substrate-binding site and non-competitive mechanisms. To determine whether 4-HPR would also inhibit aromatase activity in intact cells, MCF-7 human breast cancer cells were incubated with or without cAMP in the presence of 4-HPR. 4-HPR inhibited both basal and cAMP-induced aromatase activity in intact MCF-7 cells. The induction of aromatase mRNA expression in MCF-7 cells by cAMP was inhibited in cells treated with 4-HPR. These results indicate that 4-HPR inhibits both the enzymatic activity and expression of aromatase. These activities may play an important role in the known chemopreventive effect of 4-HPR towards breast cancer. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bahn RS, Worsham A, Speeg KV Jr, Ascoli M and Rabin D (1981) Characterization of steroid production in cultured human choriocarcinoma cells. J Clin Endocrinol Metab 52: 447–450.
Bednarek A, Shilkaitis A, Green A, Lubet R, Kelloff G, Christov K and Aldaz CM (1999) Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumours. Carcinogenesis 20: 879–883.
Blankenstein MA, van de Ven J, Maitimu-Smeele I, Donker GH, de Jong PC, Daroszewski J, Szymczak J, Milewicz A and Thijssen JH (1999) Intratumoural levels of oestrogens in breast cancer. Steroid Biochem Mol Biol 69: 293–297.
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
Brodie A, Lu Q and Nakamura J (1997) Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol 61: 281–286.
Brodie A, Lu Q and Long B (1999) Aromatase and its inhibitors. J Steroid Biochem Mol Biol 69: 205–210.
Brueggemeier RW and Katlic NE (1990) Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures. Cancer Res 50: 3652–3656.
Choate JV and Resko JA (1996) Paradoxical effect of an aromatase inhibitor, CGS-20267, on aromatase activity in guinea pig brain. J Steroid Biochem Mol Biol 58: 411–415.
Costa A, Formelli F, Chiesa F, Decensi A, De Palo G and Veronesi U (1994) Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54: 2032s–2037s.
Crist KA, Wang Y, Lubet RA, Steele VE, Kelloff GJ and You M (1997) Effect of early vs. late administration of 4-hydroxyphenylretinamide (4-HPR) on N-methyl-N-nitrosourea (MNU)-induced mammary tumourigenesis. J Cell Biochem Suppl 27: 92–99.
de Cupis A and Favoni RE (1997) Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens. Trends Pharmacol Sci 18: 245–251.
Favoni RE, de Cupis A, Bruno S, Yee D, Ferrera A, Pirani P, Costa A and Decensi A (1998) Modulation of the insulin-like growth factor-I system by N -(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br J Cancer 77: 2138–2147.
Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, Magni A and Pizzichetta M (1989) Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 49: 6149–6152.
Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, Moglia D, De Palo G, Costa A and Veronesi U (1993) Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11: 2036–2042.
Lippman SM, Heyman RA, Kurie JM, Benner SE and Hong WK (1995) Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem Suppl 22: 1–10.
Man T (1994) Solid tumours – chemoprevention with retinoids. Leukemia 8: 1785–1790.
Marth C, Bock G and Daxenbichler G (1985) Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells. J Natl Cancer Inst 75: 871–875.
Miller WR and Forrest AP (1976) Oestradiol synthesis from C19 steroids by human breast cancers. Br J Cancer 33: 116–118.
Miller WR (1996) Aromatase inhibitors – where are we now?. Br J Cancer 73: 415–417.
Moon RC and Constantinou A (1997) Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res Treat 46: 181–189.
Prall OW, Rogan EM and Sutherland RL (1998) Oestrogen regulation of cell cycle progression in breast cancer cells. Steroid Biochem Mol Biol 65: 169–174.
Sankaranarayanan R and Mathew B (1996) Retinoids as cancer-preventive agents. IARC Sci Publ 139: 47–59.
Santner SJ, Pauley RJ, Tait L, Kaseta J and Santen RJ (1997) Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. Clin Endocrinol Metab 82: 200–208.
Sasano H and Harada N (1998) Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 19: 593–607.
Shimodaira K, Fujikawa H, Okura F, Shimizu Y, Saito H and Yanaihara T (1996) Osteoblast cells (MG-63 and HOS) have aromatase and 5 α-reductase activities. Biochem Mol Biol Int 39: 109–116.
Simpson ER, Michael MD, Agarwal VR, Hinshelwood MM, Bulun SE and Zhao Y (1997) Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J 11: 29–36.
Wang TT and Phang JM (1996) Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 107: 65–71.
Yano S, Tanaka M and Nakao K (1995) Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells. Eur J Pharmacol 289: 217–222.
Yue W and Brodie AM (1997) Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture. J Steroid Biochem Mol Biol 63: 317–328.
Zhao Y, Agarwal VR, Mendelson CR and Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumour is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137: 5739–5742.
Zhou D, Clarke P, Wang J and Chen S (1996) Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. J Biol Chem 271: 15194–15202.
Zhou DJ, Pompon D and Chen SA (1990) Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50: 6949–6954.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ciolino, H., Wang, T. & Sathyamoorthy, N. Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N -(4-hydroxy-phenyl)-retinamide. Br J Cancer 83, 333–337 (2000). https://doi.org/10.1054/bjoc.2000.1269
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1269
Keywords
This article is cited by
-
Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide
Breast Cancer Research and Treatment (2013)
-
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents
Breast Cancer Research and Treatment (2012)
-
Steroidal Metabolites Transformed by Marchantia polymorpha Cultures Block Breast Cancer Estrogen Biosynthesis
Cell Biochemistry and Biophysics (2012)
-
Activation of p53, inhibition of telomerase activity and induction of estrogen receptor beta are associated with the anti-growth effects of combination of ovarian hormones and retinoids in immortalized human mammary epithelial cells
Cancer Cell International (2005)